Abstract
Introduction
Some 12 months ago a commentary was published in INNOVATIONS in Pharmacy reviewing, from the perspective of the standards of normal science, modeled technology assessment claims published in the Journal of Medical Economics from January 2015 to December 2015 1 . This systematic review concluded that of the 32 cost-effectiveness studies reviewed, none presented their claims or projections in an evaluable form and none suggested how they might be evaluated. None met the standards of normal science. The claims made for cost-effectiveness were either impossible to verify, or if potentially verifiable, were not presented in an evaluable form. The studies lacked credibility and were best seen as constructed imaginary worlds. There was no basis for assessing whether the claims were right or whether they were wrong, and in the majority of cases they would never know, as the timeframe for the analysis guaranteed that the claims were immune to failure. Reviews of studies published in Pharmacoeconomics and Value in Health over the same calendar 2015 period came to the same conclusion 2 3 .
The Journal of Medical Economics review pointed out that this lack of scientific credibility is a major concern. If medical economics is to advance through the formulation and testing of hypotheses, then editors of journals should consider whether or not to set standards for the acceptance of publications to include the requirement for evaluable claims and the results of claims assessment. If this is not acceptable, then it should be made clear that published papers are simply imaginary worlds or thought experiments. These reviews of published studies are part of a series of commentaries in INNOVATIONS in Pharmacy over the last 12 months that have focused on the evidentiary standards for claims assessment required or recommended by technology assessment agencies such as the National Institute for Health and Care Excellence (NICE) in the UK and the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, professional groups such as the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Academy of Managed Care Pharmacy (AMCP) in the US and independent research groups such as the Institute for Clinical and Economic Review (ICER) 4 5 6 7 8 9 10 . The common theme in these commentaries, and papers published earlier in the .
In case this characterization might appear as an unnecessarily harsh judgement on standards that have been in place for 30 years or more and which have generated literally thousands of published, peer review studies and evaluations by technology assessment groups, the commentaries recently pointed to the latest version of the guidelines released in March 2017 by the Canadian Agency for Drugs and Technologies in Health (CADTH). The CADTH guidelines made it quite clear that the technology assessment framework is not to be judged by the standards of normal science 14 15 . Rather, CADTH guidelines are designed to set criteria for the construction of imaginary worlds or simulations to support cost-outcomes claims; to 'inform' health system decision makers, not to test hypotheses. Presumably, within disease areas and for specific product comparisons, this additional modeled information will be added to the imaginary modeled claims already published or submitted to other agencies for the same or similar products.
The purpose of this second review of cost-effectiveness studies published in the Journal of Medical Economics is to consider whether the standards of normal science continue to be put to one side, with the Journal continuing to accept simulated, non-evaluable claims generated by imaginary worlds. The period covers January 2016 December 2016. This review follows on one recently published which revisited costeffectiveness claims in Value in Health for studies published between January 2016 and December 2016 16 . This will be followed in a forthcoming commentary that will revisit studies published in the same time period in Pharmacoeconomics.
Methods
A systematic review, following the PRISMA-P checklist (MeSH terms 'cost', 'cost effectiveness' , 'Markov', 'QALY') of all papers published in the Journal of Medical Economics in calendar 2016 was undertaken 17 . In order to judge whether the modeled claims presented met the standards of normal science four questions were considered:
• Is the study model capable of generating testable claims? • Did the study attempt to generate testable claims?
• Did the study suggest how the claims might be evaluated? • Did the study caution readers as to the implications of generating non-testable claims?
Each author independently reviewed the selected studies with consensus agreement reached on the assessment.
A testable claim was defined as one that could be evaluated empirically in a timeframe relevant to the needs of a formulary committee (ideally a period of 2 to 3 years). This period was chosen because a testable claim was seen as provisional. A product or device could, in this context, be accepted by a committee for formulary listing, but subject to an agreement with the manufacturer to report back to the committee with evidence to support the claims made. These claims could be for product comparative effectiveness, for the impact of the product on resource utilization or some combination of these to support a claim for incremental cost-effectiveness. The claim for comparative effectiveness could encompass clinical endpoints as well as those captured as patient reported outcomes (PROs).
In judging whether or not a model might support testable (1.e., falsifiable) claims, even if the possibility was not considered by the authors(s), three characteristics of the model are important. These are (i) the modeling framework, (ii) the choice of primary outcome measure; and (iii) the time frame for the model. A Markov or discreet event simulation model with a lifetime perspective and with discounted cost per QALY claims as the primary endpoints would be one where comparative claims would be impossible to evaluate. There is no chance of falsification, feedback to decision makers or replication. It would be assessed as immune to failure. Against this, a simple, trial-based decision model with a timeframe of 12 to 18 months with claims expressed in clinical (including PRO) and resource utilization endpoints would be open to hypothesis testing and feedback to a formulary committee. Even with a short-term time horizon, however, the choice of outcome may not be evaluable outside of a protocol-driven observational study. If health care systems do not collect specific QALY measures on an ongoing basis then it is impossible to evaluate cost-per-QALY willingness-to-pay threshold claims from integrated data bases. This assumes, of course, that the QALY measure that might be collected is consistent with the measure utilized in the simulation model.
While claims may be potentially evaluable, what is typically missing in modeled claims is any direction as to how the claims might be assessed in treatment practice. Presenting the same model that has been re-formulated for different markets and different countries, with the model consistently generating positive claims for a sponsor's product seems rather pointless in the absence of a protocol that proposes how the modeled claims can be evaluated. This is a feature conspicuous by its absence in technology assessment submission guidelines.
At the same time, this evaluation also searched for systematic reviews published in calendar 2016. Two questions were considered relevant:
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• Did the systematic review of economic evaluations address the issue of the credibility, evaluation and replication of clinical claims in the respective modeled economic evaluations? • Did the systematic review recommend (or caution against) accepting the claims from the modeled economic evaluations as the basis for formulary decisions?
Finally, the review considered whether or not the costeffectiveness study was funded or supported by a pharmaceutical or device manufacturer. The question addressed was whether or not the results of the costeffectiveness modeling supported the manufacturer's product.
Results
The review identified 40 cost-effectiveness studies (Table 1) together with one systematic review of economic models in moderate-to-severe asthma and COPD
18
.
Economic Models
None of the studies met the standards of normal science in providing evaluable and replicable claims in a form that could be supported by a claims assessment protocol. . In addition, if we take a cutoff of 6 years or more in the model timeframe, a further seven models would be considered to have non-evaluable claims 37 38 49 50 51 54 57 . The balance of the models with a timeframe of 5 years or less had the potential to generate or did produce claims that were potentially evaluable 20 45 46 56 . A further 3 studies utilized the lifetime IMS CORE diabetes model 22 26 42 . In addition, 4 studies utilized a Markov framework for timelines of 10, 25 and 70 years together with two studies utilizing the Cardiff Diabetes Model for 40 year time horizons 51 38 50 49 54 57 . In total, therefore, 26 of the 40 economic evaluations (65.0%) presented modeled claims that were immune to failure given the timeframe of the model.
In terms of the questions raised:
• Two thirds of the published economic evaluations failed to present credible claims that met the expected standards of normal science in presenting claims for cost-effectiveness that were potentially evaluable and replicable
• None of the studies attempted to present evaluable claims, although by default a handful of studies presented claims that could be evaluated • None of the studies considered how their claims, even if potentially evaluable, could be assessed in treatment practice • None of the studies cautioned the reader that their claims might not be evaluable and that the reader would have no idea if they were right, wrong or potentially misleading
Systematic Review
The Einarson et al systematic review of models in moderateto-severe asthma and COPD identified 53 articles, 14 of these were for patients with asthma and 39 in COPD. Models were defined under three heads: (i) prospective trial based models (8); (ii) predictive decision models (27) ; and (iii) retrospective patient record models.
Key points noted in summarizing the results were:
• 
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In terms of the two questions raised in respect of this systematic reviews of modeled claims:
• The review did not address the question of the credibility of the modeled claims, et alone issues of whether the claims were evaluable and replicable • The review did not caution the reader that in accepting the claims made that they did not meet the standards expected of normal science as inputs to the formulary evaluation process
Discussion
The fact that in those studies funded or sponsored by a pharmaceutical or device manufacturer in the Journal of Medical Economics support the manufacturer's product is, perhaps, unsurprising. After all, the previous review of modeled studies in the Journal of Medical Economics made the same observation as has the more recent review of studies in Value in Health 1 3 . Indeed, the more cynical reader may wonder why there is any surprise at all. After all, does the apparent the lack of any challenge to these published claims simply reflect the difficulty, or more appropriately, the impossibility of challenging the construction of imaginary worlds? Or, does the lack of challenge reflect a lack of interest by decision makers in imaginary worlds and their imaginary claims? Rather than taking claims at face value, holding to the belief that the standards of normal science can be put to one side by rejecting hypothesis testing in favor of 'information provision', decision makers may see these publications as marketing exercises that they can put to one side.
Discretion in Modeled Claims
It is worth recalling the 1994 Editorial in the New England Journal of Medicine regarding the discretionary nature of costeffectiveness studies and the Journal's policy on accepting such studies for review 19 . The position taken was that because of the discretionary nature of the methods used to analyze cost-effectiveness it is 'incumbent on authors journal editors and the funders of these studies to minimize any source of bias'. 20 . A recent Cochrane review of interventions to prevent misconduct and promote integrity in research and publication found that 'Overall, there is very low quality evidence that various methods of training in research integrity had some effect on participants' attitudes to ethical issues but minimal (or shortlived) effects on their knowledge' 21 .
At the same time, as noted in previous commentaries in INNOVATIONS in Pharmacy have been increasing concerns over the inability of researchers to replicate the results of RCTs. A Nature survey, reported in May 2016, found that over 70% of researchers had tried and failed to reproduce other experiments and more than half failed to reproduce their own experiments 22 . At the moment we do not seem to have struck a balance between tolerating tentative conclusions and honest errors and efforts to improve reproducibility in biomedical claims 23 .
Questioning the integrity of published clinical research is reinforced by more fundamental claims that most published research findings can be shown to be false 24 If this is accepted then further doubt is cast on those modeled claims that rely on one or two clinical trials (typically the sponsors) or on network indirect comparisons between (possibly false?) comparator trials to support the models clinical assumptions. In the absence of claims replication the clinical evidence base may be considered insufficient to support modeled claims for formulary listing and pricing. Health care decision makers would, as detailed below, be justified in asking for the clinical outcomes assumptions to be evaluated and reproduced, together with claims made for cost-effectiveness. In the case where the modeled claims are immune to failure, those sponsoring such claims run the risk of them being ignored and rejected out of hand as they fall at the first hurdle for establishing their credibility. 
Discretion and Imaginary Worlds
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Medicine is the apparent disregard for the standards of normal science; the acceptance of modeled claims for costeffectiveness that are non-evaluable. This is not a question of replication, but rather one, as noted in the introduction to this review, of immunity to failure. 22 26 42 . In addition, a further 5 studies utilized a Markov framework for timelines of 5, 7, 10, 25 and 70 years together with two studies utilizing the Cardiff Diabetes Model for 40 year time horizons 39 51 38 50 49 54 57 . None of these studies presented claims that could be evaluated.
Threshold Values
Irrespective of the choice of imaginary world, the primary purpose of the majority of these studies would appear to be to demonstrate that, given the choice of model, its structure and input variables, that the claims made for the cost-effectiveness of the sponsor's product can be considered because, unless they are shown to be dominant in respect of comparators, the cost-per-QALY clams falls with 'accepted' or 'recognized' willingness-to-pay thresholds. The thresholds deemed to be appropriate in the various studies vary widely. Some studies adopted notional willingness-to-pay thresholds with US$50,000 being popular, although, if considered appropriate, this could be extended to US$100,000 or US$150,000 to claim cost-effectiveness and appropriateness for formulary listing. Other studies adopted the NICE thresholds of £20,000 and £30,000. For studies based in European treating environments a popular threshold value was €30,000 with a few studies applying the World Health Organisation (WHO) proposed per capita GDP 3-times multiple. It is not clear whether the model outcomes determined the threshold value chosen or the threshold value determined the model. In any event, the argument is moot as the claims for threshold compatibility, including applications of probabilistic sensitivity analysis, were unevaluable. The focus in all cases appeared to support claims for the cost-effectiveness of the sponsor's product. Whether this reflects publication bias is unknown. We have no idea of how many other, potentially competing, modeled claims were developed which have not been or have yet to be published.
Given the popularity of published constructed claims that conclude that a product is cost-effective, there is surprisingly perhaps no consensus on the use of threshold values, what thresholds represent and the construction of threshold values 25 . Questions on how we might value health improvements and the opportunity cost of budgetary decisions might be more illuminating if we put to one side constructed and unevaluable incremental cost per QALY claims and focused instead on claims that are evaluable and can be reported on to health decision makers in a meaningful timeframe. As it stands, and has been pointed out again in previous INNOVATION in Pharmacy commentaries, there is no agreed standard for measuring utilities for cost-per-QALY claims and there is unlikely to be one. Although there are a number of generic and disease-specific instrument that have been promoted as the basis for utility metrics, clinical trials are typically not powered for utility endpoints. As a result the imaginary lifetime models will go to the literature to justify the choice of utility metric. As well, at least in the US, there is little interest in QALY claims and willingness to pay thresholds. The exception here being the modeled (yet unevaluable) claims, typically from a long-term or lifetime perspective, that have been promoted by the ICER to support recommendations for the 'appropriate' pricing of pharmaceutical products.
It is also worth noting that NICE, in attempting to move to a more 'flexible' version of the EQ-5D (the 'reference case' mandated instrument), adopting the EQ-5D-5level instrument as a successor to the EQ-5D-3level version has found that the two generate different utility profiles and it is not possible to crosswalk from the EQ-5D-3L to the EQ-5D-5L. This illustrates a more general point, and a strong argument for abandoning cost- 
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6 different results. Achieving a willingness-to-pay cost per QALY threshold with one instrument is no guarantee that an alternative, yet equally valid, instrument will come to the same conclusion.
Comorbidities
As noted also in previous commentaries, the presence of comorbidities and their potential impact on outcomes, costs and compliance is typically overlooked in modeled long-term claims for cost effectiveness. Given the likelihood of older patient groups presenting with one or more comorbidities this is a significant oversight by model builders. This is recognized, for example, in the Lobotesis et al assessment of combination stent-retriever thrombectomy in acute ischemic stroke 59 . The authors caution that there may be limitations in relation to resource use data where acute and long term costs are taken from a study based on patients with atrial fibrillation and an average age of 80 years. Apparently, these patients are older than those in the base case clinical study used; they also suffer from atrial fibrillation with possible additional comorbidities.
Assistance and Persistence
A further issue with modeled claims is the treatment of adherence and persistence with therapy. This is seldom acknowledged in claims made, although the fact that in many disease areas only a minority of patients are compliant after two to three years from index prescription will presumably impact long-term claims. One exception here is the qualification in the application of the CORE diabetes model that the model does not take into account 'potential differences between the respective treatments in adherence and persistence that can influence both effects and costs'. As noted in previous commentaries, it may seem pointless to model over (in this case) 50 years when patients have possibly long-ceased to persist with the therapy 26 . Also, it should be noted, the possible impact of new products entering the type 2 diabetes market and consequent therapy switching is also not considered.
Peer Reviews of Imaginary Worlds
The resources devoted by NICE and other agencies to the assessment of a manufacturer's modeled reference case costutility claims stand in contrast to the support given to peer reviewers who are asked to evaluate modeled claims for journals such as the Journal of Medical Economics and Value in Health. Given time constraints for peer review and claims by journals that they can offer 'rapid publication' and a short turnaround of papers (and you can often pay a 'quick expedition fee' to guarantee an even faster turnaround) suggests that, at best, the evaluation of a constructed imaginary world will limited. This does not imply any dereliction on the part of journal editors or unpaid peer reviewers, but is simply a fact of life. Journals do not have the luxury of investing resources on a model review to the standards of a NICE or PBAC review.
One solution to the peer review question is to establish standards for accepting or rejecting modeled claims for costeffectiveness: to ask that the paper meet two acceptance criteria: (i) that the claims are evaluable in a timeframe that is meaningful for feedback to health system decision makers; and (ii) that the model claims are supported by a protocol that details how the claims are to be evaluated in treatment practice. Perhaps as a first step journal editors (and certainly formulary committees) should reject any manuscript that begins with 'A lifetime Markov model was ….'.
Qualified Support
In a few cases modeled claims comparisons provide only qualified support for the sponsor's product. This typically occurs when the modeled lifetime cost-per-QALY estimates exceed notional willingness-to-pay thresholds. Consider, for example, the Goeree et al modeled case for nivolumab in nonsmall cell lung cancer (NSCLC) in Canada
50
. Application of a lifetime Markov model or a progression-free survival model generated cost-per-QALY estimates versus the comparators docetaxel and erlotinib in excess of $140,000. In this case, while pointing out that funding has been approved in Canada for oncology drugs where the $100,000 willingness to pay threshold has been exceeded, the authors emphasize the unmet need within NSCLC and that given the perceived NCSLC disease burden in Canada, as evidenced by its epidemiological profile, nivolumab 'has the potential to bring significant health benefits to patients in comparison to standard chemotherapy options (p. 641)'. Nivolumab is seen to 'represent(s) a major advance in disease management', 'provides unprecedented survival benefits' and a more favorable adverse event profile. These aspects were not, apparently, captured within the model framework but should, it can be argued, be factored into a willingness to accept cost-per-QALY projections which, although immune to failure, are in excess of accepted notional thresholds.
Comparing Imaginary Worlds
It is commonplace for the authors of one long-term imaginary world to compare their world with 'competitor' imaginary worlds. It is not clear what this achieves given that the various competitor models also yield claims that are typically immune to failure. All that can be achieved are claims that one model is more 'representative' of an unknown future than another model. The potential readers, if they are interested, have no basis in the absence of feedback from the evaluation of modeled claims to judge whether one model is in any way 'superior' to another. It seems such a pointless exercise. An exercise that could, presumably, continue indefinitely as manufacturer's contract with consultants to publish even more product-supporting, non-evaluable modeled claims in disease and therapy areas. While it might be unreasonable to draw to close an analogy with an imaginary world such as that represented by Gormenghast, the description of the novels in 
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7 the series as representing 'a sprawling, gothic structure' has a certain resonance 27 . But perhaps, as noted in a previous commentary, we could attempt to close the wardrobe door on Narnia and return to the real world of normal science 28 .
Discussions by authors of model 'limitations' also point to a number of common 'elements' that may limit or relegate the claims generated by the model. 
Systematic Reviews
Given the dominance of constructed imaginary worlds in costeffectiveness claims, it is reasonable to ask what role systematic reviews actually play. Apart, obviously, from the review pointing to the diversity, latitude and incompatibility of modeled claims within disease areas, it is far from clear that such reviews actually perform a useful service. This is in contrast to the Cochrane reviews, for example, which are anchored in the scientific method to support evidence-based medicine. To argue, as the CADTH guidelines so eloquently put it, that economic models are not intended to test hypotheses but merely to 'provide information', raises the question of how a formulary committee is to make sense of the diversity and incompatibility of the information presented. While it can be appreciated that sponsoring economic models to support a marketing strategy is an entirely legitimate exercise, the presence of highly technical competing yet incompatible messages is hardly a positive step forward. Are formulary committees expected to undertake a further review of systematic reviews? Perhaps, in such a review, a formulary committee following advice above to journal editors, should immediately reject any study that began 'A lifetime Markov model …'.
The overall impression from the Einarson et al systematic review is the difficulty of comparing model results and coming to any general conclusions on the imaginary claims for costeffectiveness of therapies, either against specific comparators or the 'standard of care' within either asthma or COPD 18 . In the case of omalizumab, the results varied widely, in some models supporting a cost-effectiveness case with others coming to the opposite conclusion. The results for COPD presented such variation in the choice of the primary drug and its comparators, that it is also difficult, if not impossible, to come to any meaningful conclusions that might guide formulary decision making.
While the difficulties attendant upon any attempt to 'herd the cats' in such a variable modelling environment can be appreciated, the more substantive issues of credibility, evaluation and replication are not addressed in the review. On the information presented, there is no evidence that the issue of presenting evaluable claims was addressed in any of the studies. While the issue of the face validity of the model was apparently addressed in a few studies, internal external and predictive validity were largely ignored. Unfortunately, in setting the standards for validation in terms of those proposed by ISPOR and the Society for Medical Decision Making (SMDM) in their Good Practices Research reports on constructing imaginary worlds, the authors overlooked the importance of predictive validation as standing outside face validity, internal and external validity 29 30 . A modeled claim is not to be judged on the apparent 'validity' of its structure or input assumptions. This point was made in a recent critique of modeled claims 11 12 . Predictive validity is not an option in 'validation'. Failure to consider predictive validity puts the standards of normal science to one side. Irrespective of any conclusions regarding the extent to which a model is considered to have face, internal and external validity, the only test (unless we take the claims at face value) is empirical: can the claims be validated (or at least not falsified) in treatment practice. Otherwise, all that Einarson et al have accomplished is to point to the variability in constructed imaginary worlds. The paradox is that, at least in COPD and to a lesser extent in the asthma models, the time frame for many of the models presented is one that could support evaluable claims. The possibility that the claims presented could be supported by protocols and evaluated in clinical practice was not considered.
Potentially Evaluable Claims
This review has identified a number of studies that have the potential to generate evaluable claims. These include the Einarson et al 1-year models for palperidone in schizophrenia 21 47 , the Pettigrew et al colorectal cancer model 23 , the Qin et al overactive bladder model 25 , metastatic colorectal cancer model, the Xuan et al duodenal ulcer model 52 and the Goeree et al model of opioid-induced constipation 58 . While there is the potential to generate claims for a range of outcomes and summary ICER claims (including cost-per-QALY), none of the studies considered how these claims might be evaluated in treatment practice. This raises the issue of the role claims assessment protocols might have in supporting sponsored and other comparative claims for cost-effectiveness. If a formulary committee, as proposed in the Minnesota guidelines could insist that manufacturers underwrite protocols to support, and provide feedback on, clinical and cost-effectiveness claims, ), the Journal could adopt a protocol policy which would allow for manufacturer' sponsored submissions, but with the 'integrity' of the model claims checked by the need to feed back the results of a effectiveness trial or prospective observational study.
As an additional check, the Journal could require peer reviews of both the initial modeled claims and the report of claims evaluation to be published. The former would meet any concerns as to the quality and feasibility of the claims assessment protocol while the latter would hopefully ensure that once published the claims could be assessed in other treatment environments, providing an accumulating body of evidence to support clinical and outcomes claims for the product.
Conclusions
In the recently published review of modeled cost-effectiveness claims in Value in Health, the discussion concluded on a pessimistic note: it is unlikely that present practice would be overturned. Rather, we could expect a continuation of the commitment to creating and publishing claims that are 'immune to failure'. It was pointed out that Richard Dawkins, in Unweaving the Rainbow, recognizes our willingness to feed on 'superstition, the paranormal and astrology'. Or, as he labels this, our continuing appetite for being 'Hoodwink'd with faery fancy' 33 . We might extend the reference and argue that the 'imaginary world' meme is so well entrenched in health technology assessment that the biologically valuable tendency of individuals to imitate (c.f., the Dawkins' example of the opening of milk bottle tops among European tits or American Chickadees) perpetuates the acceptance of lifetime Markov models, conferring a survival advantage to those who subscribe to the construction of imaginary worlds, supporting professional advancement. 
